Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

Chief Executive Officer John Leonard said the company is preparing a rolling biologics license application, or BLA, for lonvo-z, a one-time therapy intended to treat hereditary angioedema, or HAE.

Intellia expects to be positioned to announce FDA acceptance of the filing by the end of 2026 and is preparing for a potential U.S. approval and launch in the first half of 2027.

Leonard pointed to results from the Phase III HALO trial, which were presented at the European Academy of Allergy and Clinical Immunology meeting and published in The New England Journal of Medicine.

During the six-month primary observation period, lonvo-z reduced mean monthly HAE attacks by 87% compared with placebo, according to the company.

Sixty-two percent of patients receiving lonvo-z were attack-free and therapy-free during the observation period.

Patients in the lonvo-z arm recorded a 23-point improvement from baseline in the total angioedema quality-of-life score.

Leonard said a six-point change is considered clinically meaningful.

All patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks five through 28, according to patient-level data cited by the company.

The most common treatment-emergent adverse events were infusion-related reactions, headache and fatigue.

All reported events were Grade 1 or Grade 2, and no serious adverse events had been observed in the lonvo-z arm as of the data cutoff.

Leonard said patients in both the original treatment arm and crossover group remained free of long-term prophylaxis therapy at the data cutoff.

He also said the company believes some patients may continue to improve over time based on preclinical work and observations from its Phase I/II study.

Intellia has completed hiring for field medical, reimbursement and strategic accounts teams as it builds its commercial infrastructure.

The company said those teams are engaging treatment centers on readiness, while separate work continues on payer outreach, distribution planning and access strategy.

During the quarter, Intellia launched the HAEreframed.com disease-awareness initiative.

Leonard said the effort is intended to broaden understanding of the burdens associated with HAE, including the recurring requirements of chronic.